Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Afatinib. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR known ✓ | P00533 | 20/20 | 1.00 |
| ▸ | ERBB2 known ✓ | P04626 | 10/20 | 1.00 |
| ▸ | ERBB4 known ✓ | Q15303 | 2/20 | 1.00 |
| ▸ | GAK | O14976 | 2/20 | 1.00 |
| ▸ | ABL1 | P00519 | 2/20 | 1.00 |
| ▸ | LCK | P06239 | 2/20 | 1.00 |
| ▸ | MET | P08581 | 2/20 | 1.00 |
| ▸ | PHKG2 | P15735 | 2/20 | 1.00 |
| ▸ | BLK | P51451 | 2/20 | 1.00 |
| ▸ | IRAK1 | P51617 | 2/20 | 1.00 |
| ▸ | DYRK1A | Q13627 | 2/20 | 1.00 |
| ▸ | HIPK4 | Q8NE63 | 2/20 | 1.00 |
| ▸ | EPHA6 | Q9UF33 | 2/20 | 1.00 |
| ▸ | CIT | O14578 | 1/20 | 1.00 |
| ▸ | EPHB6 | O15197 | 1/20 | 1.00 |
| ▸ | RIPK2 | O43353 | 1/20 | 1.00 |
| ▸ | STK10 | O94804 | 1/20 | 1.00 |
| ▸ | LYN | P07948 | 1/20 | 1.00 |
| ▸ | RET | P07949 | 1/20 | 1.00 |
| ▸ | CHRM2 | P08172 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Afatinib SCHEMBL28567422 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL232772 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL2269415 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL29733662 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL2865630 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL231072 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL2865634 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL185786 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL231073 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK | |
| Afatinib SCHEMBL28409673 | 1.00 | EGFR (1.00) | EGFRERBB2GAKABL1LCK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1265 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2508521-B2 | Method for the production of amino crotonyl compounds | BOEHRINGER INGELHEIM INT (DE) | 2022-09-07 | — | — | EP | claimed |
| US-11357769-B2 | Drug combinations for reducing cell viability and/or cell proliferation | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2022-06-14 | — | — | US | claimed |
| EP-3454898-B1 | DRUG COMBINATIONS FOR REDUCING CELL VIABILITY AND/OR CELL PROLIFERATION | EISAI R&D MAN CO LTD (JP) | 2021-11-10 | — | — | EP | claimed |
| EP-3173084-B1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2019-10-23 | — | — | EP | claimed |
| US-20190117640-A1 | DRUG COMBINATIONS FOR REDUCING CELL VIABILITY AND/OR CELL PROLIFERATION | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2019-04-25 | — | — | US | claimed |
| EP-2451445-B1 | PROCESS FOR DRYING OF BIBW2992, OF ITS SALTS AND OF SOLID PHARMACEUTICAL FORMULATIONS COMPRISING THIS ACTIVE INGREDIENT | BOEHRINGER INGELHEIM INT (DE) | 2019-04-03 | — | — | EP | claimed |
| US-20180360834-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | BOEHRINGER INGELHEIM INT (DE) | 2018-12-20 | — | — | US | claimed |
| US-20180297989-A1 | PROCESS FOR THE PREPARATION OF N-[4-[(3-CHLORO-4-FLUORO PHENYL) AMINO]-7-[[(3s-TETRAHYDRO-3-FURANYL]OXY]-6-QUINAZOLINYL]-4-(DIMETHYL AMINO)-(2E)-2-BUTENAMIDE (2Z)-2-BUTENEDIOATE (1 :2) AND ITS POLYMORPHS THEREOF | MSN LABORATORIES PRIVATE LIMITED (IN) | 2018-10-18 | — | — | US | claimed |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | PRINCIPIA BIOPHARMA INC. | 2018-07-12 | — | — | US | claimed |
| US-20180086744-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | BOEHRINGER INGELHEIM INT (DE) | 2018-03-29 | — | — | US | claimed |
| WO-2004004775-A1 | NOVEL DRUG COMPOSITIONS BASED ON NOVEL ANTICHOLINERGICS AND INHIBITORS OF EGFR-KINASE | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2004-01-15 | — | — | WO | claimed |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-12-04 | — | — | US | claimed |
| WO-2003094921-A2 | UTILIZATION OF INHIBITORS OF EGFR-MEDIATED SIGNAL TRANSDUCTION FOR THE TREATMENT OF BENIGN PROSTATIC HYPERPLASIA (BPH)/PROSTATIC HYPERTROPHY | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-11-20 | — | — | WO | claimed |
| EP-1345910-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2003-09-24 | — | — | EP | claimed |
| US-20030158196-A1 | Pharmaceutical compositions based on anticholinergics and EGFR kinase inhibitors | BOEHRINGER INGELHEIM PHARMA GMBH CO. KG (DE) | 2003-08-21 | — | — | US | claimed |
| WO-2003068264-A1 | NEW MEDICINAL COMPOSITIONS ON THE BASIS OF ANTICHOLINERGIC AGENTS AND EGFR KINASE INHIBITORS | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-08-21 | — | — | WO | claimed |
| WO-2003066060-A2 | USE OF TYROSINE KINASE INHIBITORS FOR THE TREATMENT OF INFLAMMATORY PROCESSES | BOEHRINGER INGELHEIM PHARMA GMBH & CO.KG (DE) | 2003-08-14 | — | — | WO | claimed |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-08-07 | — | — | US | claimed |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-11-21 | — | — | US | claimed |
| WO-2002050043-A1 | QUINAZOLINE DERIVATIVES, MEDICAMENTS CONTAINING SAID COMPOUNDS, THEIR UTILIZATION AND METHOD FOR THE PRODUCTION THEREOF | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2002-06-27 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180360834-A1 | QUINAZOLINE DERIVATIVES FOR THE TREATMENT OF CANCER DISEASES | NQO2, NRAS, ABL1 | EGFR 1758/4885ERBB2 1557/4885ERBB4 1535/4885 |
| US-20180297989-A1 | PROCESS FOR THE PREPARATION OF N-[4-[(3-CHLORO-4-FLUORO PHENYL) AMINO]-7-[[(3s-TETRAHYDRO-3-FURANYL]OXY]-6-QUINAZOLINYL]-4-(DIMETHYL AMINO)-(2E)-2-BUTENAMIDE (2Z)-2-BUTENEDIOATE (1 :2) AND ITS POLYMORPHS THEREOF | CYP4B1, CYP1B1, CYP2S1 | EGFR 4240/4885ERBB2 2343/4885ERBB4 2489/4885 |
| US-20020173509-A1 | Quinazoline derivatives and phamaceutical compositions containing them | MAP3K1, MAP4K2, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16 | EGFR 195/4885ERBB2 78/4885ERBB4 152/4885 |
| US-11357769-B2 | Drug combinations for reducing cell viability and/or cell proliferation | FGFR4, ERBB4, FGFR3 | EGFR 4/4885ERBB2 11/4885ERBB4 2/4885 |
| US-20180193274-A1 | COMPOSITIONS FOR ILEO-JEJUNAL DRUG DELIVERY | BTK, LCK, DSTYK | EGFR 228/4885ERBB2 52/4885ERBB4 349/4885 |
| US-20030149062-A1 | Use of tyrosine kinase inhibitors for the treatment of inflammatory processes | ERBB2, EGFR, ERBB4 | EGFR 2/4885ERBB2 1/4885ERBB4 3/4885 |
| US-20030225079-A1 | Use of inhibitors of the EGFR-mediated signal transduction for the treatment of benign prostatic hyperplasia (BPH)/prostatic hypertrophy | BPHL, EGFR, ERBB3 | EGFR 2/4885ERBB2 4/4885ERBB4 6/4885 |
| US-20180086744-A1 | COMBINATION TREATMENT OF CANCER COMPRISING EGFR/HER2 INHIBITORS | EGFR, ERBB2, ERBB3 | EGFR 1/4885ERBB2 2/4885ERBB4 4/4885 |
| US-20190117640-A1 | DRUG COMBINATIONS FOR REDUCING CELL VIABILITY AND/OR CELL PROLIFERATION | FGFR4, ERBB4, FGFR3 | EGFR 4/4885ERBB2 11/4885ERBB4 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.